Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
Driehaus Micro Cap Growth DMCRX
- NAV / 1-Day Return 13.68 / +0.51 %
- Total Assets 300.3 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.410%
- Distribution Fee Level High
- Share Class Type No Load
- Category Small Growth
- Investment Style Small Growth
- Min. Initial Investment 10,000
- Status Limited
- TTM Yield 0.73%
- Turnover 128%
USD | NAV as of Sep 28, 2024 | 1-Day Return as of Sep 28, 2024, 12:12 AM GMT+0
Morningstar’s Analysis DMCRX
Will DMCRX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 19.9
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Northern Institutional US Govt Sel | 3.30 | 9.3 Mil | Cash and Equivalents |
Crinetics Pharmaceuticals Inc | 3.16 | 8.9 Mil | Healthcare |
Modine Manufacturing Co | 2.49 | 7.0 Mil | Consumer Cyclical |
TransMedics Group Inc | 2.35 | 6.6 Mil | Healthcare |
Rhythm Pharmaceuticals Inc | 1.85 | 5.2 Mil | Healthcare |
Xenon Pharmaceuticals Inc | 1.81 | 5.1 Mil | Healthcare |
Arlo Technologies Inc | 1.76 | 4.9 Mil | Industrials |
Alkami Technology Inc | 1.71 | 4.8 Mil | Technology |
EverQuote Inc Class A | 1.61 | 4.5 Mil | Communication Services |
Veeco Instruments Inc | 1.59 | 4.5 Mil | Technology |